Publications by authors named "Steve Nanchen"
Article Synopsis
- - The study evaluated the efficacy and safety of lotilaner (Credelio™ CAT) for flea control in cats, finding that it provided a significantly higher flea kill rate compared to fipronil + S-methoprene over a 90-day duration.
- - A total of 343 cats across 11 veterinary clinics participated, with treatments administered on days 0, 30, and 60, and flea counts measured at multiple intervals.
- - Results revealed that 98.3% of lotilaner-treated cats were flea-free by day 90, while only 28.8% of those on the fipronil + S-methoprene treatment were flea-free, indicating lotilaner's superior
Article Synopsis
- The ixodid tick Amblyomma cajennense, common in parts of the Americas, poses health risks to humans and animals due to its ability to carry pathogens like Rickettsia rickettsii.
- A study with Beagle dogs assessed the effectiveness of lotilaner, an oral chewable tablet, against tick infestations, showing its rapid efficacy in killing ticks within 48 hours post-treatment.
- Results indicated that lotilaner provided 100% efficacy shortly after administration and maintained over 99% efficacy for at least 30 days without any adverse effects reported.
Article Synopsis
- The Australian paralysis tick (Ixodes holocyclus) secretes a neurotoxin that can paralyze domestic pets, affecting around 10,000 pets annually.
- Lotilaner, a new chewable tablet for dogs, shows rapid effectiveness against these ticks, with studies confirming its efficacy over a three-month period.
- Results indicate that dogs treated with lotilaner were free of live ticks within 48 to 72 hours, maintaining 95% effectiveness through the study, affirming its ability to quickly eliminate tick infestations.
Article Synopsis
- Haemaphysalis longicornis ticks are identified as carriers of Babesia gibsoni, leading to severe anemia in dogs in Japan, Korea, and China; this study focused on the effectiveness of lotilaner chewable tablets (Credelio) against these tick infestations.
- Twenty-two Beagles were used in the experiment; they were divided into treated and control groups, where one group received lotilaner while the other was sham-treated, with tick counts monitored over several days following infestations.
- The results showed that lotilaner was highly effective, achieving a 57.4% reduction in tick numbers within the first 12 hours and maintaining significant differences in tick counts between treated and control dogs after each infestation
Article Synopsis
- - A study was conducted across 20 clinics in Europe to evaluate the effectiveness and safety of lotilaner versus fipronil for treating tick infestations in cats, focusing on a minimum dosage of 6.0 mg/kg of lotilaner.
- - Results showed that lotilaner demonstrated a significantly higher efficacy (98.3-100%) in reducing tick counts compared to fipronil (89.6-99.6%), particularly on several assessment days, establishing lotilaner as a superior treatment option.
- - Both treatments were well tolerated by cats and successfully administered by owners throughout the study period, indicating practicality for use in real-world settings.
Article Synopsis
- Lotilaner is a new oral ectoparasiticide for cats, showing effective and prolonged flea control for at least one month, based on prior lab studies.
- A field study involving 121 households in Europe compared the efficacy of Lotilaner with a topical treatment (fipronil/(S)-methoprene) in controlling fleas and flea allergy dermatitis (FAD).
- Results indicated Lotilaner provided a significantly higher efficacy (97.2% on Day 14 and 98.1% on Day 28) compared to fipronil/(S)-methoprene (48.3% and 46.4% respectively), with at least 81% of Lotilaner-treated cats being
Article Synopsis
- Lotilaner, a chewable tablet approved for dogs and now also for cats (Credelio), offers a safe and effective way to control ticks in felines compared to topical treatments.
- Three key studies evaluated its effectiveness after a single oral dose of about 6 mg/kg against Ixodes ricinus ticks, measuring results at various intervals.
- Results showed over 99% efficacy in killing ticks within specified timeframes, with no significant adverse effects noted, confirming lotilaner's suitability as a parasiticide for cats.
Article Synopsis
- - Lotilaner, a chewable tablet for cats, was developed as a safe and effective option against fleas, specifically targeting Ctenocephalides felis, with studies assessing its efficacy and speed of action.
- - Two legally conducted laboratory studies involved giving cats the recommended dose of 6 mg/kg of lotilaner and evaluating its effectiveness against fleas 24 hours after treatment and at subsequent weekly infestations for up to 35 days.
- - Results showed that lotilaner was 100% effective at killing fleas within 24 hours and maintained over 97% efficacy as early as 8 hours post-treatment, with no reported adverse effects, demonstrating it was well-tolerated in cats.
Article Synopsis
- Lotilaner (Credelio™) is a new oral treatment for flea infestations in dogs, developed to work quickly and effectively against ectoparasites.
- In a study involving Beagles, dogs were grouped and treated with lotilaner or left untreated, with flea counts measured at various intervals following treatment.
- The results showed that while there was no significant reduction in flea counts at 30 minutes and 1 hour, a 64% reduction was observed at 2 hours, increasing to 99.6% effectiveness at 8 hours, with no adverse effects reported.
Article Synopsis
- Lotilaner is a new oral medication for dogs that effectively kills fleas and ticks, showing high efficacy (over 99%) for at least 84 days after treatment in a field study conducted across Europe.
- In the study, 128 households received lotilaner and 64 received fipronil, with results showing lotilaner was consistently more effective at eliminating fleas than fipronil, with at least 90% of treated dogs flea-free.
- Lotilaner chewable tablets were found to be tasty and well-tolerated by dogs, successfully alleviating symptoms of flea allergy dermatitis, including itching.
Article Synopsis
- A study tested a new flea and tick treatment for dogs, lotilaner (Credelio™), showing it provided rapid and sustained knockdown of fleas for at least three months.
- The trial involved 111 dogs receiving lotilaner and 50 receiving afoxolaner (Nexgard®), with significant reductions in flea counts seen within a month for both treatments.
- Lotilaner had a 100% flea-free rate by Day 90, while both treatments were well-accepted by dogs and effectively managed symptoms of flea allergy dermatitis.
Article Synopsis
- Lotilaner chewable tablets (Credelio™) for dogs show rapid tick-killing action and sustained efficacy for at least 35 days.
- A study conducted in Europe involved 19 clinics, comparing lotilaner's efficacy with another product (FSM) in treating ticks on client-owned dogs.
- Results indicated that lotilaner provided significantly greater tick count reductions (over 99% efficacy by Day 56) compared to FSM, and both treatments were well-tolerated by dogs.
Article Synopsis
- Lotilaner is a treatment for dogs that effectively controls infestations of common ticks, reducing the risk of pathogen transmission.
- Eight studies were conducted to test its efficacy against different tick species, including Dermacentor variabilis and Rhipicephalus sanguineus, using a standardized treatment protocol.
- The results showed that lotilaner achieved 100% effectiveness against existing tick infestations, with very few minor side effects reported.
Article Synopsis
- Dogs are at risk of Babesia spp. infections, leading to a study on the effectiveness of lotilaner (Credelio™) against Babesia canis.
- In two studies, dogs were divided into treatment and control groups, with some receiving lotilaner and others receiving no treatment while being exposed to infected ticks.
- The results showed that all control dogs became infected with B. canis, while all lotilaner-treated dogs remained free of the infection, demonstrating the treatment's 100% efficacy.
Article Synopsis
- Lotilaner (Credelio™) is an effective new treatment for controlling tick infestations in dogs, showing rapid efficacy and sustained results against prevalent tick species in Europe.
- Two studies involving Beagle dogs demonstrated that optimized doses of lotilaner led to a significant reduction in live ticks, with 100% effectiveness reported in most assessments.
- The findings indicate lotilaner as a reliable option for tick control, with no live ticks found on treated dogs shortly after treatment and minimal re-infestation rates over time.
Article Synopsis
- - Lotilaner, a new tick treatment for dogs, is highly effective, killing 98% of ticks for over a month after administering a chewable tablet.
- - In a study, dogs treated with lotilaner showed a 69.8% reduction in live tick counts within 4 hours and a near-total elimination (99.2%) at 8 hours post-treatment.
- - Lotilaner's efficacy remained strong over repeated infestations, with significant differences in tick counts observed compared to untreated dogs, and no adverse side effects reported.
Article Synopsis
- Lotilaner is a new oral insecticide and acaricide for dogs that effectively kills fleas, with a half-life of 30 days allowing prolonged efficacy.
- Four studies were conducted to assess how quickly and effectively lotilaner can kill fleas after a single treatment, showing it achieves over 99% efficacy within the first 8 hours and maintains high effectiveness for 35 days.
- The results suggest that regular monthly use of lotilaner can help disrupt flea populations and mitigate health risks associated with flea infestations in dogs, with no observed adverse effects.
Two libraries of enantiomerically pure imidazolium salts bearing an oxazoline unit were synthesized. Deprotonation of the imidazolium salts and complexation of the resulting oxazoline-carbene ligands to iridium(I) was achieved in one step by mixing the imidazolium salts with NaOtBu and [(eta(4)-cod)IrCl](2) in THF at room temperature. The air-stable complexes were purified by flash chromatography.
View Article and Find Full Text PDFThe determination of residual dipolar couplings (RDCs) by quantitative J spectroscopy methods such as Heteronuclear Single Quantum Correlation with Phase Encoded Coupling (HSQC-PEC) is prone to systematic errors that may be caused by differential attenuation during the conversion of orthogonal density operator components into observable terms. The attenuation may be caused by miscalibration of radio-frequency pulses and by relaxation effects. A simple method is presented that allows one to remove most of these systematic errors without losses in sensitivity or resolution.
View Article and Find Full Text PDF